This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
by Indrajit Bandyopadhyay
MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.
Strong Segmental Performance to Drive Stryker's Q1 Earnings?
by Zacks Equity Research
SYK's first-quarter 2025 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
DXCM Q1 Earnings to Reflect U.S. Coverage Expansion & Stelo Impact?
by Zacks Equity Research
DexCom Q1 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
Will BAX's Q1 Earnings Improve Following Transformation Completion?
by Zacks Equity Research
Baxter's first-quarter results are likely to reflect the favorable impact of kidney care sales. Growth in infusion therapies, pharmaceuticals and patient support systems to continue.
Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?
by Zacks Equity Research
RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.
Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is the Options Market Predicting a Spike in Globus Medical (GMED) Stock?
by Zacks Equity Research
Investors need to pay close attention to Globus Medical (GMED) stock based on the movements in the options market lately.
Will Segmental Performance Drive West Pharmaceutical's Q1 Earnings?
by Zacks Equity Research
West Pharmaceutical Services' first-quarter results are likely to reflect growth amid pharma stabilization, biologics rebound & contract manufacturing gains.
Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
International Growth Drives GMED Stock Amid Fierce Competition
by Zacks Equity Research
Globus Medical is gearing up for a series of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
GMED Stock May Benefit Following the Acquisition of Nevro
by Zacks Equity Research
Globus Medical acquires Nevro Corp. to expand its presence in the $2.50 billion musculoskeletal market.
GMED Stock Jumps 41.8% in a Year: What's Behind the Rally?
by Zacks Equity Research
Globus Medical's robust musculoskeletal offerings and synergies from the NuVasive merger are fueling its stock gains.
Should You Hold Globus Medical Stock in Your Portfolio Now?
by Zacks Equity Research
GMED stays on investors' radar due to its high NuVasive-merger synergies and solid Musculoskeletal prospects.
New Product Launches Benefit GMED Stock Amid Macro Issues
by Zacks Equity Research
Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
Globus Medical Expands Anterior Spine Portfolio With Two New Offerings
by Zacks Equity Research
GMED announces the commercial launch of COHERE ALIF Spacer and Modulus ALIF Blades.
Is the Options Market Predicting a Spike in Globus Medical (GMED) Stock?
by Zacks Equity Research
Investors need to pay close attention to Globus Medical (GMED) stock based on the movements in the options market lately.
Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RFG
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips
by Zacks Equity Research
GMED's fourth-quarter 2024 performance reflects strong synergies from the NuVasive merger.
Globus Medical (GMED) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Globus Medical (GMED) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Globus Medical (GMED) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 10.53% and 2.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical (GMED) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Get a deeper insight into the potential performance of Globus Medical (GMED) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
DexCom (DXCM) Misses Q4 Earnings Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of -10% and 0.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.